4Siegel R,Naishadham D,Jemal A. Cancer statistics,2013[J].CA: A Cancer Journal forClinicians,2013,63(1): 11-30.
5Wagner AD, Orothe W, Haerting J, et al. Chemotherapy in advanced gastric cancer: a systematic review and meta- analysis based on aggregate data [J ]. Journal of Clinical Oncology,2006,24(18) : 2903-2909.
6Xu X, Wang L, Xu HQ, et al. Clinical Comparison between Paclitaxel Liposome(Lipusu)and Paclitaxel for Treatment of Patients with Metastatic Gastric Cancer[J]. Asian Pacific Journal of Cancer Prevention, 2013,14(4) : 2591-2594.
7Trotti A, Colevas AD, Setser A, et al. CTCAE v3. 0: development of a comprehensive grading system for the adverse eft'ects of Cancer treatment[J]. Semin Radiat Oncol, 2003,13(3) : 176-181.
8Park SC, Chun HJ. Chemotherapy for Advanced Gastric Cancer: Review and Update of Current Practices[J]. Gut and Liver,2013,7(4) : 385-393.
9Van Cutsem E,Moiseyenko VM,Tjulandin S,et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group [J]. Journal of Clinical Oncology,2006,24(31) : 4991-4997.
10Straubinger RM, Arnold RD, Zhou R, et al. Antivascular and antitumor activities of liposome-associated drugs [ J ]. Anticancer Res,2004,24(2a) : 397- 404.
